Advertisement

SN Comprehensive Clinical Medicine

, Volume 1, Issue 12, pp 1060–1064 | Cite as

Plasma Concentrations of Protein Z and Protein Z-Dependent Protease Inhibitor in Thalassemia Major Patients

  • Majid Ghazanfari
  • Mohammad Ali Jalali Far
  • Saeed Shirali
  • Zari Tahannejad AsadiEmail author
Medicine
  • 46 Downloads
Part of the following topical collections:
  1. Topical Collection on Medicine

Abstract

Thalassemia is the most common congenital hemolytic disorder by a partial or complete deficiency in globin chain synthesis. Recent investigations have suggested a correlation between protein Z (PZ) and protein Z-dependent protease inhibitor (ZPI) deficiency and thrombosis. So, the aim of this study was to evaluate the PZ and ZPI levels in beta (β)-thalassemia patients. In this study, 40 patients with thalassemia major and 40 control subjects were selected. PZ and ZPI serum levels were measured by sandwich ELISA technique. PZ and ZPI were significantly higher in thalassemic patient group than control group. Also, PZ levels and PLT and Hb counts were significantly higher in splenectomized thalassemic patients than non-splenectomized ones. The exact mechanism of increased PZ and ZPI have an impact on hypercoagulable state in β-thalassemia major could not be found in our study. More studies are still needed to understand these challenges in β-thalassemia major patients.

Keywords

Thalassemia major Protein Z Protein Z-dependent protease inhibitor Plasma Coagulability state 

Introduction

Thalassemia is an inherited hemolytic disease and one of the most common genetic disorders worldwide. Thalassemia is caused by a decreased or abnormal synthesis of alpha (α) or beta (β) globin chains which results in α- or β-thalassemia respectively. It is common in the Mediterranean region, the Far East, and South America but more prevalent in Southeast Asia. Incidence rate of thalassemia is estimated at about 1 in 100,000 annually [1, 2]. However, the life expectancy has noticeably improved in thalassemic patients as a consequence of chronic blood transfusion together with iron chelation therapies in recent years [3, 4], but clinical evidence has shown that thalassemic patients have a higher incidence risk of thromboembolic events [5]. The overall incidence rate of thromboembolic events has been reported in thalassemia major, ranging from 0.9 to 4%, while higher rates have been estimated in thalassemia intermedia patients (3.9–29%) [2, 3]. Several factors pathophysiologically are involved in thromboembolic events such as deep vein thrombosis (DVT), pulmonary embolism, and port vein thrombosis in patients with thalassemia major and intermedia [1].

The most important factors involved in hypercoagulability state of thalassemia are alterations in the membrane lipid components of abnormal RBCs resulting in an increased exposure of phosphatidyle serin (PS) which in turn can reinforce the conversion of prothrombin to thrombin through its procoagulant activity, especially in splenectomized patients, thrombosis following splenectomy, cardiac dysfunction, and liver dysfunction followed by reduced protein C and protein S [1, 6].

Several studies have reported the potential role of changes in protein Z (PZ) levels in hypercoagulability state [7, 8, 9]. PZ is a plasma single-chain vitamin K-dependent protein which was detected in human plasma in 1984; however, its physiologic function remained unknown until 1998. Its structure is similar to that of factor VII, IX, X, and protein C [10, 11]. Unlike these proteins, PZ is not a zymogen of a serin protease, because it lacks SER and HIS residues of catalytic triad [12]. In vitro and in vivo studies showed that PZ, like protein C and protein S, can act as an anticoagulant [13]. PZ functions as cofactor of protein Z-dependent protease inhibitor (ZPI) resulting in inactivation of factor Xa. ZPI is an anticoagulant protein and a member of serpin superfamily synthesized in the liver and inhibits factor Xa in the presence of PZ, Ca2+, and phospholipid, but can inactivate factor XIa in the absence of these cofactors. PZ and ZPI circulate in plasma as a complex [11, 14]. Some studies have suggested a correlation between low levels of PZ and the risk of ischemic stroke [7, 15], while another study has reported an increased risk of ischemic stroke in high levels of PZ presence [16]. Until recently, the role of PZ and its correlation with the incidence risk of thromboembolic events have been an area of controversy. Thus, the aim of this study was to investigate PZ and ZPI levels in patients with β-thalassemia major and their relationships with coagulability state in these patients.

Material and Methods

Study Group: Patients and Samples

In this study, 40 patients with thalassemia major (24 (60%) males, 16 (40%) females (5–40 years old, median age 18.2) were included in this study after morphologic and clinical examinations. Subjects receiving drugs that affect hemostasis (anticoagulants), those who were consuming alcohol, taking contraceptive drugs, and pregnant subjects were excluded from the study. Forty healthy subjects, who were proportionally sex and age matched, were selected as the control group. The control group had no clinical symptoms of thalassemia or other diseases, and all their laboratory tests were normal based on clinical examination and test results. All peripheral blood (PB) samples were obtained from the Gachsaran Shahid Rajaee Hospital during 4 months with written informed consent from the subjects. This study was approved by the local ethics committee of Ahvaz Jundishapur University of Medical Sciences (AJUMS.REC.1393.277) and was conducted within 4 months.

Blood Sampling and Sandwich ELISA Technique

Five milliliters of PB samples were collected from all subjects, immediately before transfusion in patients, in tubs containing EDTA anticoagulant and centrifuged at 3200g for 15 min within 1 h, and plasma was collected and stored at − 80° until the time of assay. Then, PZ and ZPI were measured by sandwich ELISA technique (Cusabio Kit, Behring ELISA processor instrument).

Statistical Analysis

The results were expressed as mean ± standard error (SE) (range), and variations between the data of two sets were analyzed by t test. Relationship between proteins was assessed by use of the Mann-Whitney test. p value < 0.05 was considered statistically significant.

Results

PZ and ZPI were significantly higher in the thalassemic patient group than the control group (p = 0.004, p = 0.001 respectively). From 40 patients, 30 (75%) were non-splenectomized patients (5–25 years old, median age 16.17) with 6–14 transfusion dependency time (median 8 months). In addition, 10 (25%) were splenectomized patients (14–40 years old, median age 24.3) with 6–60 transfusion dependency time (median 19 months) (Table 1). There was no significant difference in ZPI levels between non-splenectomized and splenectomized patients, but PZ levels were significantly higher in splenectomized thalassemic patients than non-splenectomized ones (p = 0.015).
Table 1

Comparison of the PZ and ZPI serum levels in thalassemia major patients and control subjects

Variables

Group 1 thalassemic

Group2 control

p value

NO.

40

40

 

Sex

F:M; 16:24

F:M; 16:24

 

Age

18.2 (5-40)

18.2 (5-40)

 

ZPI, μg/mL (mean ± 2SE)

1.53 ± 0.48

0.5 ± 0.24

p = 0.001

PZ, ng/mL (mean ± 2SE)

1031 ± 230

621 ± 156

p = 0.004

NO. number, PZ protein Z, ZPI protein Z-dependent protease inhibitor

There was a significant difference in platelet (PLT) count between non-splenectomized thalassemic and splenectomized patients (p = 0.002). Also, a statistically significant difference between Hb levels was found between these two groups (p = 0.006) (Table 2).
Table 2

Comparison of the PZ and ZPI serum levels with PLT and Hb in splenectomized and non-splenectomized thalassemia major patients

Variables

Non-splenectomized

Splenectomized

p value

NO.

30

10

 

Age

16.17 (5–25)

24.3 (14–40)

 

Transfusion period

16 days

17 days

 

Transfusion dependency time, mean (range)

8 months (6–14)

19 months (6–60)

 

PLT (mean ± 2SE)

283 ± 37.4

519.3 ± 147.8

p = 0.002

Hb, g/dL (mean ± 2SE)

8.5 ± 0.34

8.6 ± 0.44

p = 0.006

ZPI, μg/mL (mean ± 2SE)

1.28 ± 0.44

2.28 ± 1.34

p = 0.077

PZ, ng/mL (mean ± 2SE)

872 ± 252

1507 ± 410

p = 0.015

NO. number, PZ protein Z, ZPI protein Z-dependent protease inhibitor, PLT platelet, Hb hemoglobin

Discussion

PZ is a plasma vitamin K-dependent glycoprotein acting as a cofactor of ZPI to inhibit factor Xa together with Ca2+ and phospholipid [17]. Recent studies have represented evidences on the potential role of this protein in thromboembolic complications [13]. Therefore, in this study, investigation of PZ and ZPI levels in patients with thalassemia major and their possible correlations with coagulability was done in these patients.

In the current study, a significant difference in PZ and ZPI levels was found in patients with thalassemia rather than the control subjects. In contrast, Del Vecchio et al. in 2007 have shown reduced levels of PZ in thalassemic patients rather than in healthy subjects by ELISA method [18]. In addition, Gris et al. in 2002 and Bretelle et al. in 2005 have suggested that low serum levels of PZ were associated with thrombosis risk in patients with pregnancy complications by ELISA method [19, 20]. The mean difference of PZ levels in several studies was supposed to be due to PZ responses to inflammatory reactions or the influence of gene polymorphisms on gene expression values [21, 22, 23]. In confirmation of the inflammatory response hypothesis, the data published by Kobelt et al. in 2001 showed that PZ levels were increased at the time of ischemic stroke incidence [21]. Cesari et al. in 2007 reported that PZ levels were elevated in acute phase of coronary artery diseases and it began to reduce about 3 months after an acute onset by ELISA method [24]. In addition, Girard et al. in 2013 have precisely investigated the response of PZ and ZPI to inflammatory state, and they consequently showed that the ZPI was an acute phase protein while the elevation of PZ in inflammatory responses was derived from increased ZPI [25]. Some studies have shown that infection and inflammation are the second leading cause of death in patients with major thalassemia [26]. But Bolkun et al. in 2013 revealed that due to FVIII deficiency in hemophilia A patients, PZ and ZPI levels were higher than the control group by the ELISA method in their study [27]. Therefore, although a similar technique has been used in our study and other studies and according to controversy results, PZ and ZPI levels can be increased in inflammatory and anti-thrombotic conditions, but still more studies are needed to confirm this in patients with thalassemia.

In our study, PZ levels were significantly higher in splenectomized patients than non-splenectomized ones, but there was no significant difference in ZPI levels between these two groups. In addition, a significant difference in PLT and Hb count was found between non-splenectomized and splenectomized patients. Schettini et al. in 1987 reported that hemostatic system in patients with thalassemia major was changed and protein C levels and also PLT count were increased in splenectomized patients with thalassemia major by ELISA technique [28]. But, Angchaisuksiri et al in 2007, confirmed the platelet activation, inflammation, impaired fibrinolysis with elevated levels of factors such as thrombinantithrombin, beta2 thromboglobulin, C-reactive protein (CRP), tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) in splenectomized patients with E/β-thalassemia and anticoagulants factors such as protein C, S, anti-thrombin, and fibrinogen were significantly decreased in these patients in comparison with non-splenectomized patients by ELISA technique [29]. In addition, Hashemieh et al. in 2016 showed that protein C, S, fibrinogen, and factor V activity were decreased in patients with thalassemia intermedia, in comparison with the control group, and splenectomy has no significant effect on hemostatic factors except activity of D-dimer in these patients [30]. Therefore, the results of our study and other studies have approximately confirmed the coagulability challenges, but still, more studies are needed to understand its exact mechanism in thalassemia patients.

There is also evidence of oxidation of membrane components contributing in the pathophysiology of β-thalassemia. The excess of free α-globin chains can induce ROS formation via binding to iron and heme resulting in oxidative damage of lipids, proteins, and nucleic acid. Lipid peroxidation and protein oxidation cause loss of membrane lipid organization and deformity of the cell. The consequence of these alterations is the exposure of PS [31]. It has been suggested that PS acts as a recognition signal of damaged RBCs by phagocytes of reticuloendothelial system, their removal, and apoptosis [18]. Therefore, these damaged cells remain in circulation in splenectomized subjects. Thalassemic RBCs enhance thrombin production with negatively charged PSs on their surface, and consequently, anticoagulants such as PZ are increased to prevent thrombotic events.

In brief, the results of our study did not show the exact influence of PZ and ZPI on provoking the hyperactivity of coagulative system and increased risk of vascular thromboembolism in patients with major thalassemia, but PZ can be suggested to decrease thrombotic events in splenectomized patients.

Conclusions

In this study, PZ and ZPI were significantly higher in thalassemic patients. Also, PZ levels, PLT, and Hb count were significantly higher in splenectomized thalassemic patients. The results of our study cannot exactly show the PZ and ZPI influence on coagulative system, but can suggest that PZ and ZPI are increased in inflammatory and anti-thrombotic conditions to prevent thrombotic events. But still, more studies are required to confirm the exact mechanism of PZ and ZPI in coagulation and thrombotic challenges in β-thalassemia major patients.

Notes

Authors’ Contributions

Z.T.A have conceived the manuscript and revised it. M.Gh and M.A. J wrote the manuscript. M.A. J and S. S provided the clinical data, pathological diagnoses, and information. M.Gh performed the technical tests.

Funding Information

This paper is issued from the thesis of Majid Ghazanfari, MSc student of hematology and blood banking. This work was financially supported by grant th93/26 from vice chancellor for research affairs of Ahvaz Jundishapur University of Medical Sciences.

Compliance with Ethical Guidelines

Conflicts of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of local ethics committee of the Ahvaz Jundishapur University of Medical Sciences (AJUMS.REC.1393.277) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Cappellini MD. Coagulation in the pathophysiology of hemolytic anemias. ASH Education Program Book 2007;2007(1):74–78.CrossRefGoogle Scholar
  2. 2.
    Sirachainan N. Thalassemia and the hypercoagulable state. Thromb Res. 2013;132(6):637–41.CrossRefGoogle Scholar
  3. 3.
    Cappellini M, Robbiolo L, Bottasso B, Coppola R, Fiorelli G. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000;111(2):467–73.CrossRefGoogle Scholar
  4. 4.
    Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev. 2008;22(5):283–92.CrossRefGoogle Scholar
  5. 5.
    Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99(1):36–43.CrossRefGoogle Scholar
  6. 6.
    Seregina EA, Nikulina OF, Tsvetaeva NV, Rodionova MN, Gribkova IV, Orel EB, et al. Laboratory tests for coagulation system monitoring in a patient with β-thalassemia. Int J Hematol. 2014;99(5):588–96.CrossRefGoogle Scholar
  7. 7.
    Heeb MJ, Paganini-Hill A, Griffin JH, Fisher M. Low protein Z levels and risk of ischemic stroke: differences by diabetic status and gender. Blood Cell Mol Dis. 2002;29(2):139–44.CrossRefGoogle Scholar
  8. 8.
    Santacroce R, Sarno M, Cappucci F, Sessa F, Colaizzo D, Brancaccio V, et al. Low protein Z levels and risk of occurrence of deep vein thrombosis. J Thromb Haemost. 2006;4(11):2417–22.CrossRefGoogle Scholar
  9. 9.
    Van Goor M, Dippel D, Jie K-G, De Maat M, Koudstaal P, Leebeek F. Low protein Z levels but not the protein Z gene G79A polymorphism are a risk factor for ischemic stroke. Thromb Res. 2008;123(2):213–8.CrossRefGoogle Scholar
  10. 10.
    Pardos-Gea J, Ordi-Ros J, Serrano S, Balada E, Nicolau I, Vilardell M. Protein Z levels and anti-protein Z antibodies in patients with arterial and venous thrombosis. Thromb Res. 2008;121(6):727–34.CrossRefGoogle Scholar
  11. 11.
    Sofi F, Cesari F, Tu Y, Pratesi G, Pulli R, Pratesi C, et al. Protein Z-dependent protease inhibitor and protein Z in peripheral arterial disease patients. J Thromb Haemost. 2009;7(5):731–5.CrossRefGoogle Scholar
  12. 12.
    Ichinose A, Takeya H, Espling E, Iwanaga S, Kisiel W, Davie EW. Amino acid sequence of human protein Z, a vitamin K-dependent plasma glycoprotein. Biochem Biophys Res Commun. 1990;172(3):1139–44.CrossRefGoogle Scholar
  13. 13.
    Yin Z-F, Huang Z-F, Cui J, Fiehler R, Lasky N, Ginsburg D, et al. Prothrombotic phenotype of protein Z deficiency. Proc Natl Acad Sci. 2000;97(12):6734–8.CrossRefGoogle Scholar
  14. 14.
    Huang X, Yan Y, Tu Y, Gatti J, Broze GJ, Zhou A, et al. Structural basis for catalytic activation of protein Z–dependent protease inhibitor (ZPI) by protein Z. Blood. 2012;120(8):1726–33.CrossRefGoogle Scholar
  15. 15.
    Vasse M, Guegan-Massardier E, Borg J-Y, Woimant F, Soria C. Frequency of protein Z deficiency in patients with ischaemic stroke. Lancet. 2001;357(9260):933–4.CrossRefGoogle Scholar
  16. 16.
    McQuillan AM, Eikelboom JW, Hankey GJ, Baker R, Thom J, Staton J, et al. Protein Z in ischemic stroke and its etiologic subtypes. Stroke. 2003;34(10):2415–9.CrossRefGoogle Scholar
  17. 17.
    Ndonwi M, Lu L, Tu Y, Phillips M, Broze G Jr. Functional analysis of protein Z (Arg255His) and protein Z-dependent protease inhibitor (Lys25Arg and Ser40Gly) polymorphisms. Br J Haematol. 2008;143(2):298–300.CrossRefGoogle Scholar
  18. 18.
    Del Vecchio GC, Nigro A, Giordano P, Schettini F, Altomare M, Pietrapertosa A, et al. Plasma protein Z and protein C inhibitors and their role in hypercoagulability of thalassemia. Acta Haematol. 2007;118(3):136–40.CrossRefGoogle Scholar
  19. 19.
    Gris J-C, Quéré I, Dechaud H, Mercier E, Pinçon C, Hoffet M, et al. High frequency of protein Z deficiency in patients with unexplained early fetal loss. Blood. 2002;99(7):2606–8.CrossRefGoogle Scholar
  20. 20.
    Bretelle F, Arnoux D, Shojai R, D'Ercole C, Sampol J, Dignat F, et al. Protein Z in patients with pregnancy complications. Am J Obstet Gynecol. 2005;193(5):1698–702.CrossRefGoogle Scholar
  21. 21.
    Kobelt K, Biasiutti FD, Mattle HP, Lämmle B, Wuillemin WA. Protein Z in ischaemic stroke. Br J Haematol. 2001;114(1):169–73.CrossRefGoogle Scholar
  22. 22.
    Karakoyun S, Gürsoy MO, Kalçık M, Yesin M, Gündüz S, Astarcıoğlu MA, et al. The role of protein Z and protein Z-dependent protease inhibitor polymorphisms in the development of prosthetic heart valve thrombosis. Anatol J Cardiol. 2016;16(5):361.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Gorski MM, Lotta LA, Pappalardo E, De Haan HG, Passamonti SM, van Hylckama VA, et al. Single nucleotide variant rs2232710 in the protein Z-dependent protease inhibitor (ZPI, SERPINA10) gene is not associated with deep vein thrombosis. PLoS One. 2016;11(3):e0151347.CrossRefGoogle Scholar
  24. 24.
    Cesari F, Gori AM, Fedi S, Abbate R, Gensini GF, Sofi F. Modifications of protein Z and interleukin-6 during the acute phase of coronary artery disease. Blood Coagul Fibrinolysis. 2007;18(1):85–6.CrossRefGoogle Scholar
  25. 25.
    Girard T, Lasky N, Tuley E, Broze G. Protein Z, protein Z-dependent protease inhibitor (serpinA10), and the acute-phase response. J Thromb Haemost. 2013;11(2):375–8.CrossRefGoogle Scholar
  26. 26.
    Cappellini M-D, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Infections in thalassaemia major. 2008.Google Scholar
  27. 27.
    Bolkun L, Galar M, Piszcz J, Lemancewicz D, Kloczko J. Plasma concentration of protein Z and protein Z-dependent protease inhibitor in patients with haemophilia A. Thromb Res. 2013;131(3):e110–3.CrossRefGoogle Scholar
  28. 28.
    Schettini F, De Mattia D, Arcamone G, Sabato V, Altomare M, Burattini MG, et al. Coagulation contact phase factors and inhibitors in β-thalassemia major children. Pediatr Hematol Oncol. 1987;4(3):231–6.CrossRefGoogle Scholar
  29. 29.
    Angchaisuksiri P, Atichartakarn V, Aryurachai K, Archararit N, Chuncharunee S, Tiraganjana A, et al. Hemostatic and thrombotic markers in patients with hemoglobin E/β-thalassemia disease. Am J Hematol. 2007;82(11):1001–4.CrossRefGoogle Scholar
  30. 30.
    Hashemieh M, Azarkeivan A, Sheibani K. A comparison of hemostatic changes in splenectomized and nonsplenectomized β-thalassemia intermedia patients. J Pediatr Hematol Oncol. 2016;38(8):636–41.CrossRefGoogle Scholar
  31. 31.
    Grandone E, Colaizzo D, Cappucci F, Cocomazzi N, Margaglione M. Protein Z levels and unexplained fetal losses. Fertil Steril. 2004;82(4):982–3.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Thalassemia & Hemoglobinopathy Research Center, Health research instituteAhvaz Jundishapur University of Medical SciencesAhvazIran
  2. 2.Department of Laboratory Sciences, Faculty of ParamedicineAhvaz Jundishapur University of Medical SciencesAhvazIran

Personalised recommendations